news 

Oncoscience grants GenIlac the rights to apply for marketing approval for nimotuzumab in Turkey and for marketing the antibody in the territory.

Oncoscience will take an active advisory role guiding GenIlac in the conduct of clinical trials and aid in the compilation of regulatory documentation for the approval process at the Turkish Ministry of Health.

The cooperation will result in faster recruitment in already ongoing studies. Additionally new indications will be explored.

„We are very happy to have found such an able partner in GenIlac who has a leading role in Turkey based on the company’s product portfolio. GenIlac is a privately owned company and the two companies’ firm philosophies are nearly identical“ said Ferdinand Bach, CEO of Oncoscience AG. „The data generated in this cooperation will suppelement data for regulatory purposes and lead to faster market entry for nimotuzumab(Theraloc®)“.

Abidin Gülmüs ,CEO of Gen Ilac added ‘‘Oncoscience and GenIlac complement each other very well in their market and product views. We are very much excited to serve the Oncology Society with unmet needs with a non toxic EGFr antibody to the Turkish patients in the near future.“

 
09.10.2009 Wedel, Germany
Oncoscience AG presents results from Phase III study of Nimotuzumab (Theraloc®) in patients with diffuse intrinsic pontine glioma at the 41. SIOP, Sao Paulo, Brazil, October 6th-9th, 2009


On Friday October 9th, 2009 results from the Phase III study of the monoclonal antibody Nimotuzumab were presented.

At the world’ s convention for pediatric oncology in Sao Paulo data were presented that show that Nimotuzumab in combination with radiotherapy achieves comparable results in patients with diffuse intrinsic pontine glioma as
combination of aggressive chemotherapy and radiotherapy. The results do however differ significantly in the much lower side-effect profile observed with the Nimotuzumab treatment.

Children are able to stay at home, even attending school or kindergarten while undergoing antibody therapy. Response to study treatment after 24 weeks was 75%. Median survival of all patients was
recorded at 9,6 months, where responders had a median survival of 11,4 months.

After one year 34% of patients were still alive.
The results from this first-line therapy study are consistent with the excellent response rate for recurrent patients (ASCO 2008) and serve to further confirm the excellent tolerability of Nimotuzumab compared to aggressive chemotherapy, absence of side-effects commonly associated for other monoclonal antibodies and diarrhoea or exanthema caused by concomitant medications.

The results from this first-line therapy study are consistent with the excellent response rate for recurrent patients (ASCO 2008) and serve to further confirm the excellent tolerability of Nimotuzumab compared to aggressive chemotherapy, as well as absence of side-effects commonly associated for other EGFR - monoclonal antibodies like diarrhoea or drug related exanthema.



04.10.2008 Wedel, Germany
Funcrypta – Poster presentation at European Bioperspectives

Oncoscience AG is a member of the German Funcrypta project. Within the scope of this cooperation a poster will be presented at European Bioperspectives, Hannover, 7.-9. Oct. 2008. Preview the poster here (.pdf)

Visit the project website:
http://www.funcrypta.de

 European Bioperspectives: http://www.bioperspectives.org/

22.04.2008 Wedel, Germany
Oncoscience AG receives EU orphan drug status for the EGFR monoclonal antibody Nimotuzumab (Theraloc®) for the treatment of pancreatic cancer.

Oncoscience AG announced that their anti-cancer drug Nimotuzumab (Theraloc®) has been designated an orphan drug by the European Medicines Agency (EMEA) for the treatment of pancreatic cancer.

OSAG has licensed nimotuzumab for Europe and 20 other countries around the European area and will market the drug under the name „Theraloc®“.

Currently a phase III trial with patients suffering from pancreatic cancer is being conducted. The placebo, double blinded, controlled study in patients with unresectable, metastatic pancreatic cancer compares Gemcitabine + Placebo versus Gemcitabine + Nimotuzumab. At the moment only patients from Germany are enrolled in the study; furthermore patients will be recruited from other parts of the Oncoscience territory.
An additional phase III trial investigating a type of brain cancer, diffuse intrinsic pontine glioma in paediatric patients, is ongoing. Patient recruitment started in April 2006 and was concluded by August 2007. Results from this study are expected to be released during the second half of 2008.
A third phase III trial is being conducted with adult glioma patients suffering grade IV tumors. Patients are randomized and receive a combination therapy of radiation+temozolomide +/- nimotuzumab. Out of the 150 patients needed for the study, 30% have already been recruited.
Oncoscience AG already hold marketing approval in the Ukraine since October 2007 and applied for marketing approval in Europe (EMEA), Switzerland and Russia.

Wedel, October 26th, 2007
The European Medicines Agency, EMEA, concludes its formal validation of the marketing authorization application for Theraloc® (Nimotuzumab) positively

The application for marketing authorization of Theraloc® (Nimotuzumab) was submitted to EMEA on October 4th, 2007.

After formal validation the application was accepted by the EMEA on October 25th, 2007.

October 25th, 07 has also been set as “day 0” of the application procedure. The list of questions from EMEA is expected in February 2008 (day 120)

The acceptance of the marketing authorization application of Theraloc® -and thus the initiation of the authorization procedure- is the biggest milestone in the six year history of the biotech company Oncoscience AG, in Wedel, Germany.

Oncoscience AG, a biotechnology company based in Wedel, Germany is currently conducting three phase III clinical trials with the monoclonal EGFR- antibody, Nimotuzumab.

1. Phase III study of 1st line treatment in children with diffuse intrinsic pontine glioma in combination with radiotherapy
2. Phase III study in adult patients with grade IV brain tumors after surgery and adjuvant radiotherapy plus chemotherapy
3. Phase III study of 1st line therapy in patients with inoperable pancreatic cancer plus chemotherapy

Wedel, October 13th, 2007
Oncoscience AG reports marketing authorization approval for Theraloc® (Nimotuzumab) in the Ukraine

On October 12th, 2007 Theraloc® was approved in the Ukraine by the Ministry of Health of Ukraine.

As of now Theraloc® is approved for therapy of cancers of the head and neck, grade III and IV brain tumors of adult patients, as well as for therapy in children with recurrent anaplastic astrocytoma grade III, glioblastoma grade IV, and with diffuse intrinsic pontine glioma.

The marketing authorization approval is an important step for additional marketing authorization approvals in the Europe. The approval also confirms that the direction of the development program is justified and that data are sufficiently qualified.

Theraloc® will be made available to patients in the Ukraine as soon as possible and the approval for the medication in Europe will be actively pursued.

Oncoscience AG, a biotechnology company based in Wedel, Germany is currently conducting three phase III clinical trials with the monoclonal EGFR- antibody, Nimotuzumab.

1. Phase III study of 1st line treatment in children with diffuse intrinsic pontine glioma in combination with radiotherapy
2. Phase III study in adult patients with grade IV brain tumors after surgery and adjuvant radiotherapy plus chemotherapy
3. Phase III study of 1st line therapy in patients with inoperable pancreatic cancer plus chemotherapy

Wedel, September 12th 2007
ONCOSCIENCE AG ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III TRIAL OF NIMOTUZUMAB, IN FIRST LINE TREATMENT OF CHILDREN WITH INOPERABLE BRAIN CANCER

Clearance Received for Two Additional Late-Stage Trials in Adult Glioma and Pancreatic Cancer

Today Oncoscience AG (Wedel, Germany) announced, about the development of the humanized EGFR-targeting monoclonal antibody, nimotuzumab, has recruited the 40th and final patient in its trial combining nimotuzumab with radiation for the treatment of children and adolescents suffering from diffuse intrinsic pontine glioma (DIPG), an inoperable form of cancer for which treatment options are severely limited.

The Phase III trial was conducted by an international group of paediatric oncologists under the lead of principal investigator Professor Udo Bode from University of Bonn, Germany. The primary end-point of the trial is progression-free survival; secondary endpoints are survival, response rate and improvement of neurological symptoms. Results are expected end of first half 2008.

In addition, Oncoscience has advised that two additional late-stage trials have been cleared to commence in Europe:

• A randomized multi-centre study in which nimotuzumab and the current standard of care (radiotherapy with concomitant and adjuvant temozolamid) will be compared to the current standard of care in patients with glioblastoma multiforme (GBM). The study is expected to recruit 190 patients within 24 months. The primary end-point for this trial is Progression-Free Survival, with Response Rate and Symptom Control among the secondary endpoints.
  Nimotuzumab has received Orphan Drug designation from EMEA.
• A randomized multi-centre study in chemotherapy-naive patients suffering from locally advanced or metastatic pancreatic cancer who will be treated with either gemcitabine plus nimotuzumab or gemcitabine plus placebo is expected to recruit 188 patients within 24 months. The primary end-point for this trial is Response Rate with Overall Survival among the secondary endpoints.
• YM BioSciences, the licensor of nimotuzumab, anticipates that it will extend the European trial in pancreatic cancer into Canada by submitting the protocol to Canadian health regulatory authorities to add Canadian site to accelerate recruitment

Wedel, Germany, June 08 2007
ONCOSCIENCE AG ANNOUNCES FINAL RESULTS OF A PHASE-II STUDY IN PEDIATRIC PATIENTS WITH RECURRENT HIGH-GRADE MALIGNANT GLIOMA TREATED WITH THE MONOCLONAL ANTIBODY NIMOTUZUMAB DIRECTED AGAINST EGF-R, AS MONOTHERAPY.

Final results of the Phase II trial were described in an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) on Sunday, June 3rd 2007, in Chicago, by Professor Dr. Udo Bode, University of Bonn, Germany, the Principal Investigator of the study (Abstract #2006).

The trial included 47 heavily pre-treated patients with a median age of 11 years of which 45 were evaluable for response (11 patients with anaplastic astrocytoma (AA) grade III, 13 with glioblastoma multiforme (GBM) grade IV and 21 with diffuse intrinsic pontine glioma (DIPG)). All the AA and GBM patients had undergone surgery and were treated with radiation and multiple courses of different chemotherapy. The DIPG patients were treated with radiation and multiple courses of different chemotherapy.

The most important inclusion criteria were: documented progressive disease by MRI (independently assessed by a reference radiologist) at the time of entry into the study and expected survival time of not less than four weeks.

Nimotuzumab monotherapy was administered at a dose of 150 mg/m² weekly for six weeks (an induction period) and, for patients who had not progressed following induction period, treatment continued once every three weeks until week 21 or disease progression (consolidation period). First MRI assessment at week 8 shows 2 PR and 14 SD which results in a 35.6% response rate. Twelve out of 45 patients entered for consolidation therapy; four partial responses (PR), two stable disease (SD) and six disease progressions (PD) were reported. In the 21 patients with DIPG an overall clinical benefit rate of 38.1% was observed (1 PR, 7 SD) in the induction phase. In the consolidation phase, four of the eight patients with DIPG received additional clinical benefit (3 PR, 1 SD). The median survival in patients with clinical benefit was three times longer (8.9 months compared to 3.3 month) as in patients who did not respond to treatment. This length of survival in patients with recurrent disease approaches the historical median survival for newly diagnosed paediatric patients with high malignant glioma. Even more important was the observation that in these end stage patients the unexpectedly long median survival was accompanied by an excellent quality of life. No drug related rash, diarrhoea, conjunctivitis etc. (which normally is reported with use of EGFR antibodies) has been seen. Some patients were no longer wheel chair bound, and were able to feed themselves, attend kindergarten or school and have long home rather than institutional care.”

Based on these results, a first line Phase-III study in 40 paediatric patients newly diagnosed with DIPG was initiated in March 2006 and recruitment is expected to be completed in Q3/2007.

Oncoscience AG is a private company in Germany focused principally in oncology. Oncoscience AG licensed the monoclonal antibody, nimotuzumab, from CIMAB and CIMYM Inc. a majority-owned subsidiary of YM BioSciences Inc., in Canada.

Wedel, September 30th 20055
YM BioSciences partner Oncoscience AG reports update of pediatric brain cancer data
Nimotuzumab (Theraloc;TheraCIM h-R3) Phase II results awarded best poster prize at the 37^th congress of the International Society of Paediatric Oncology

Download: YM BioSciences pr9-27-05.pdf (20k) 

Wedel, March 1st 2005
YM BioSciences and Oncoscience Report Response Rate of 35.3% in Pediatric Glioma
TheraCIM h-R3 (nimotuzumab) Phase II Results Presented at European High Grade Glioma Conference

MISSISSAUGA, ON, Feb. 28 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA) today announced that it has been advised by its European partner, Oncoscience AG, that a Phase II trial in children with brain cancer (glioma) utilizing the EGF receptor monoclonal antibody TheraCIM h-R3 (nimotuzumab, "Theraloc" in Europe) as a monotherapy achieved a response rate of 35.3%. Six of the 17 children who were fully evaluable at the time of the conference were reported to have demonstrated either stable disease or a partial response. Of the six, four were identified by investigators to have been suffering from pontine glioma (diffuse intrinsic brain stem glioma) - a form of the disease that is particularly aggressive and generally untreatable. No skin toxicity or allergic reactions were reported, consistent with all the previous trials conducted with TheraCIM h-R3. These results were formally presented on February 25th, 2005 at the "European High-Grade Glioma Meeting" in Regensburg, Germany and a conference call to discuss these data will be held today at 1:00pm EST.

Phase II Trial Results
The trial included 20 children who had been treated surgically for their glioma and had also received radiation and mono chemotherapy or combination chemotherapy treatment. They were entered into the trial when all prior treatments had failed and progression had been documented by MRI assessment. One child was determined to be ineligible and was withdrawn. The trial's protocol required the trial to stop for futility if no patients responded to the treatment with h-R3; to continue as monotherapy if two patients responded, and to stop for success if at least three patients responded to treatment with the antibody. At the time of the conference, 17 of the 19 patients were available for evaluation at eight weeks after induction therapy. Response was documented by MRI in week eight and 21 after the start of therapy and evaluated centrally using the RECIST criteria. Of the six children (35.3%) in the trial who were reported to have responded to treatment, five had stable disease and one was evaluated as a partial response. Of the six patients diagnosed with intrinsic pons glioma at primary tumour diagnosis, four children (66%) responded to treatment with the antibody. One of the inclusion criteria was that patients had a minimum expected lifespan of four weeks. The survival noted in the responding patients at the time of the report were respectively: greater than 8.0; 5.0; greater than 4.0; greater than 3.5; greater than 3.0; and 1.3 months, in contrast to the non-responders who had a median and average lifespan of 1.15 months with a range of 0.3-2.0 months. No skin toxicity or allergic reactions were reported. No severe hematological or non-hematological side effects associated to the h-R3 antibody were noted and no side effects were noted in 95% of patients. The trial was conducted at seven of the 52 hospitals that compose the BFM (Berlin, Frankfurt and Munster) Group of hospitals in Germany. The principal investigator was Prof. Dr. U. Bode, Department of Pediatric Hematology/Oncology, University of Bonn. The positive results of the trial permit Oncoscience to apply for an IND to conduct a pivotal trial testing the combination of the h-R3 antibody with radiation against radiation alone for the first line treatment of pediatric glioma. If approved, the pivotal trial could start in Q2/2005, possibly include up to 100 patients and possibly recruit all patients within 12 months following initiation. TheraCIM h-R3/Theraloc/nimotuzumab is a humanized monoclonal antibody licensed from CIMAB S.A., the corporation representing the Center of Molecular Immunology in Havana.

YM and Oncoscience AG will host a teleconference on the data presented at the European High-Grade Glioma Meeting on Monday, February 28, 2005 at 1:00pm EST which may be accessed by calling +1-416-695-7860 (from Europe) or 1-800-565-5185 (in North America) and utilizing the participant code 261890.

About Oncoscience AG
Oncoscience AG is a private biotech company based in Germany and is focused in Oncology (Theraloc), Organ Transplantation (Lifor) and Tumor Banking including research in the Genome/Proteome field.

About YM BioSciences
YM BioSciences Inc. is a cancer drug development company. Its lead drug, tesmilifene, is a small molecule chemopotentiator currently undergoing a 700-patient pivotal Phase III trial in metastatic and recurrent breast cancer. Published results from tesmilifene's first Phase III trial demonstrated a substantial increase in survival in the same indication for women treated with the combination of tesmilifene and chemotherapy compared to chemotherapy alone, which demonstrated that tesmilifene significantly enhanced the therapeutic effect of chemotherapy. In addition to tesmilifene, the Company is developing the EGFr humanized monoclonal antibody described above and a GnRH anti-cancer vaccine that is in earlier stage clinical trials.

Wedel, January 10th 2005
YM BIOSCIENCES AND ONCOSCIENCE ACHIEVE CLINICAL MILESTONE
Results Permit Pediatric Brain Cancer Trial to be Converted into Pivotal Randomized First-Line Therapy Trial

MISSISSAUGA, Canada - January 25, 2005 - 
YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA) today announced that it has been advised by its European partner, Oncoscience AG, that the Phase II trial in children with brain cancer (glioma) utilizing the EGF receptor monoclonal antibody (h-R3) as a monotherapy achieved the clinical milestone that permits conversion of the trial into a pivotal trial in this population.

The new study will be a randomized Phase III trial comparing radiation (the standard-of-care) to radiation plus h-R3 as a first-line therapy following surgery. YM has been advised that the trial is expected to enroll 100 patients and is targeted for completion in the second quarter of 2006. Results from the original trial will be formally presented at the "European High-Grade Glioma Meeting" on February 25-26, 2005 in Regensburg, Germany.

"Although the results are preliminary in nature, we have been advised that at least three patients responded to the treatment, allowing the early conversion of the trial into a more significant pivotal trial. This is a welcome and unanticipated result in a patient population for whom no other therapy is available and prognosis is very poor," said David Allan, Chairman of YM BioSciences.

The study is being conducted in Germany by YM's partner in Europe, Oncoscience AG, and is the first trial of this antibody as a monotherapy and its first trial in children.

"Early termination of the trial for success in this heavily pretreated patient group and the consequent ability to proceed to a first-line therapy study is more than expected. We are looking forward to seeing the entire data set in a few weeks," stated Ferdinand Bach, CEO of Oncoscience AG.

Eighteen children were recruited into the original trial and are available for response evaluation. Patients were treated with the humanized EGFr monoclonal antibody, nimotuzumab (TheraCIM h-R3 in North America and Theraloc in Europe). The patients, for whom the prognosis is extremely poor and the expected survival period short, had brain cancer which had progressed following all other available therapies (surgery, radiation and combination or mono-chemotherapy). Under the protocol, the trial would have been terminated if no patients had responded to the monotherapy. Alternatively, it would have continued as a monotherapy with an additional 29 patients if two of the 18 patients responded and moreover, would have been defined as having achieved a sufficient response if at least three patients responded to the treatment, permitting a follow-on trial with h-R3 as a first-line (post-surgery) therapy, combining the antibody with radiation.

Commenting on these results, Dr. Paul Keane, Director of Medical Affairs at YM said, "Although the results are preliminary in nature, the early termination for success, i.e. exceeding the predefined threshold, thus allowing the initiation of a first-line therapy study in which the combination of antibody with radiation will be compared with radiation alone, is encouraging for the continued development of the drug. The combination of h-R3 with radiation has been shown effective in other trials, and these results are consistent with those obtained with other EGF receptor monoclonal antibodies."

In previous clinical trials in adult glioma, head and neck cancer and nasopharyngeal cancer, TheraCIM h-R3/Theraloc has been shown to significantly improve the therapeutic effects of radiation. A report on one of these trials was published in the Journal of Clinical Oncology (Volume 22, #9, May 1, 2004) and other trials have been described in press releases by YM BioSciences Inc.

A parallel monotherapy trial, also being conducted in Germany in metastatic pancreatic cancer, was initiated at the end of November 2004, has enrolled 14 patients to date and is targeted to complete its first clinical assessment in mid-2005 following the review of the first 30 patients in that trial. Application has been made for a randomized trial in adults with glioma and the trial in children could be supportive of that application.

Theraloc/TheraCIM has been awarded Orphan Drug designation by both the European health regulatory authority - EMEA - and by the FDA in the USA for treatment of glioma.

H-R3 is licensed to YM's subsidiary, CIMYM, for Europe, North America and the Pacific Rim excluding China, by CIMAB S.A, the commercial arm of the Center for Molecular Immunology in Havana.

YM and Oncoscience AG will host a teleconference on the data presented at the European High-Grade Glioma Meeting immediately following that conference on Monday, February 28, 2005 at 1:00pm EST and may be accessed by calling +1-416-695-7860 (from Europe) or 1-800-565-5185 (in North America) and utilizing the participant code 261890.

About YM BioSciences
YM BioSciences Inc. is a cancer drug development company. Its lead drug, tesmilifene, is a small molecule chemopotentiator currently undergoing a 700-patient pivotal Phase III trial in metastatic and recurrent breast cancer. Published results from tesmilifene's first Phase III trial demonstrated a substantial increase in survival in the same indication for women treated with the combination of tesmilifene and chemotherapy compared to chemotherapy alone which demonstrated that tesmilifene significantly enhanced the therapeutic effect of chemotherapy . In addition to tesmilifene, the Company is developing the EGFr humanized monoclonal antibody described above and a GnRH anti-cancer vaccine that is in earlier stage clinical trials.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Wedel, October 2004
Oncoscience AG announced a change in the board of directors
Oncoscience AG announced that Mrs. U. Bach, one of the founder, has left the board of directors for personnel reasons. The board of directors and the chairman thanked Mrs. Bach for the outstanding work she has done in the early phase of Oncoscience.

The owner voted during the shareholders’ general meeting in September 2004 unanimously for Mr. M.Rüdiger (Chairman, Crédit Suisse Germany) as the new member on the board of directors.The owner, board of Directors and the chairman of Oncoscience are impressed that Mr. Rüdiger is willing to work for the company and are highly motivated for the upcoming business.

Wedel, October 2004
Oncoscience AG established scientific advisory board
Oncoscience AG  is proud to inform about the establishment of the scientific advisory board with the first come together mid September 2004.

Members are well known scientist from different areas:

Prof. Dr. H. Allgayer (experimental surgery)
Prof. Dr. F. Boeminghaus (Urology)
Prof. Dr. H. Schweim ( Pharmacology )
PD.  Dr. D. Strumberg (Internal Oncology)

Chairman and the board of directors are thankful to thee readiness to give advise to Oncoscience AG in the different scientific and medical areas the company is working.

Even in the first meeting the are several different opinions which should play a role for future decisions. The advisory board will be grown by another at least two  scientist in the very near future.

Wedel, August 10th 2004
YM BioSciences' EGFr antibody receives EU orphan drug designation through Oncoscience AG, its European partner

10.08.2004 - Mississauga. YM BioSciences Inc., the cancer drug development company with an advanced-stage portfolio, and its majority-owned subsidiary, CIMYM Inc., announced that their anti-cancer drug TheraCIM hR3 has been designated an Orphan Drug by the European Medicines Agency for the Evaluation of Medical Products (EMEA) for the treatment of glioma. This designation was obtained by Oncoscience AG, the Company's European development partner for the drug. TheraCIM hR3 is licensed to YM's subsidiary CIMYM Inc. by the Center for Molecular Immunology.

"Orphan drug status provides TheraCIM hR3 with up to ten years of market exclusivity in Europe, greatly enhancing this product's commercial potential," said David Allan, Chairman and CEO of YM BioSciences. "It also ensures that assistance in meeting European regulatory requirements is provided, strengthening our regulatory position for this important cancer drug."

TheraCIM hR3, a humanized monoclonal antibody, is licensed as "Theraloc" to Oncoscience AG for Europe and is currently in a Phase I/II trial in paediatric glioma, a form of brain cancer, for which the first patients were recruited in June 2004. Oncoscience is proposing to initiate several additional studies for TheraCIM hR3, including a Phase III registration trial in adult glioma that is anticipated to start in Q4, 2004 and a Phase II trial in metastatic pancreatic cancer also anticipated to start in Q4, 2004. Results of a previous Phase I/II trial for TheraCIM hR3 were published in the Journal of Clinical Oncology on May 1, 2004.

"The combination of this orphan drug designation immediately preceding the launch of a Phase III registration trial in the designated indication is highly significant for the development of this drug," said Ferdinand Bach, CEO of Oncoscience. "We are especially proud to have obtained this designation within only six months thanks to the excellent work of our dedicated team."

On July 15, 2004, YM BioSciences announced that an agreement between it and CancerVax Corporation of San Diego, CA for two other cancer products it licensed from the Centre of Molecular Immunology was approved by the US Treasury Department.

YM BIOSCIENCES INC. 
© Bionity.COM / Chemie.DE Information Service GmbH http://www.bionity.com/news/details.php3?cmid=39017&language=e

Wedel, June 30th 2004
Orphan-Drug-Designation finalised
Oncoscience AG announces that it finalised the Orphan-Drug-Designation for its monoclonal antibody h-R3 (Theraloc) with the European Agency (Emea) on June, 24th 2004. Oncoscience AG is waiting for a decision within the next three months.

Wedel, June 11th 2004
Phase-II-Study started
Oncoscience AG announces the start of the Phase-II-Study - Therapy of high malignant gliomas by children. 27 hospitals in Germany are participating in this protocol. In a two-step-version, a maximum of 47 patients has to be enrolled in that trial. They will be treated after the first recurrence with the monoclonal antibody h-R3 (Theraloc). The first patient has already been recruited.

Wedel, March 2004
AACR annual meeting 2004 - Late breaking news
read the abstract "Establishing continuous single cell cultures from primary tumor excisions using a new generation of tumor tissue transport- and culture solution", that will be presented during AACR annual meeting 2004 in Orlando / Florida.

Download: AACR_2004.pdf  (32k) 

Wedel / MISSISSAUGA, Kanada, November 2003
Oncoscience signs contract with YM Biosciences Inc.
Read the press release

Download: press_release_YM_Biosciences.pdf (27k)